

Synthesis of Quaternary Carbon Centered Indolo[1,2-*a*]quinazolinones and Indazolo[1,2-*a*]indazolones via C-H Functionalization

K. Gogoi[†], B. R. Bora[†], G. Borah[§], B. Sarma[‡], and S. Gogoi^{†,*}

[†]Applied Organic Chemistry, Chemical Sciences & Technology Division, CSIR-North East Institute of Science and Technology, Jorhat-785006, AcSIR, Ghaziabad-201002, India,

[§]Department of Chemistry, Dibrugarh University, Dibrugarh-786004, and [‡]Department of Chemical Sciences, Tezpur University, Tezpur-784028, India

Supporting Information


Contents	Page
General Experimental	3
Experimental Procedures	3-5
Reference	5-6
Spectral and Analytical data	6-22
NMR spectra	19-65

1. General Information

Melting points were measured with a Buchi B-540 melting point apparatus and are uncorrected. NMR spectra were recorded on Bruker Avance III 500 MHz FT NMR spectrometer using tetramethylsilane (TMS) as an internal standard. All the commercially available reagents were used directly as received. All experiments were monitored by thin layer chromatography experiment. TLC was performed on Merck TLC Silica gel 60 F254 precoated plates. Column chromatography was performed on silica gel (100-200 mesh, Merck). HRMS data were recorded by electron spray ionization with a Q-TOF mass analyzer.

2. Reaction Procedures

2.1 General procedure for the synthesis of 1-phenyl-1,2-dihydro-3*H*-indazol-3-ones (**1**)¹



Scheme SI-1: Synthesis of indazolone derivatives **1**

To a stirred solution of isatoic anhydride (12.0 mmol) in ethanol (20 mL), phenylhydrazine (12.0 mmol) was added. The reaction mixture was refluxed for 2 hours and then it was allowed to cool to room temperature and kept standing at same temperature for 12 hours. The precipitated hydrazide was filtered out and washed with ethanol. Then, 25 mL of 1.0 M HCl was added into this hydrazide. To this slurry, NaNO₂ (18.0 mmol, in 10 mL water) was added and the reaction mixture was refluxed for three hours after adding 25 mL of ethanol. The solvent was reduced in vacuo and the reaction mixture was kept overnight. The solid formed was filtered out get the starting compound **1**.

2.2 General procedure for the synthesis of indoloquinazolinones **3** and indazoloindazolones **4**

A mixture of 1-phenyl-1,2-dihydro-3*H*-indazol-3-one (**1**, 0.1 mmol), alkyne (**2**, 0.1 mmol), [$\text{RuCl}_2(p\text{-cymene})_2$] (5.0 mol %) and CsOAc (0.1 mmol) in *t*-AmOH (3.0 mL) was stirred at 95 °C under open air for 24 hours. The solvent *t*-AmOH was removed under vacuo and water

was added in to the crude reaction mixture which was then extracted with ethylacetate (25 mL x 2). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 20% EtOAc in hexane as the eluant to afford indoloquinazolinone derivatives **3** and indazoloindazolones **4**.

2.3 Gram scale synthesis of **3aa**

A mixture of **1a** (840 mg, 4.0 mmol), **2a** (712 mg, 4.0 mmol), [{RuCl₂(*p*-cymene)}₂] (122 mg, 5.0 mol %) and CsOAc (768 mg, 4.0 mmol) in *t*AmOH (25 mL) was stirred at 95 °C under open air for 24 hours. The solvent *t*AmOH was removed under vacuo and water was added in to the crude reaction mixture which was then extracted with ethylacetate (30 mL x 3). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 20% EtOAc in hexane as the eluant to afford **3aa** (1.16 g, 75%).

2.4 Synthesis of **4aj** in the presence of TEMPO

A mixture of **1a** (21 mg, 0.1 mmol), **2j** (11 mg, 0.1 mmol), [{RuCl₂(*p*-cymene)}₂] (3 mg, 5.0 mol %), TEMPO (16 mg, 0.1 mmol) and CsOAc (19 mg, 0.1 mmol) in *t*AmOH (3.0 mL) was stirred at 95 °C under open air for 24 hours. The solvent *t*AmOH was removed under vacuo and water was added in to the crude reaction mixture which was then extracted with ethylacetate (25 mL x 2). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 20% EtOAc in hexane as the eluant to afford **4aj** (8 mg, 23%).

2.4 D/H Exchange reaction for the synthesis of **1a-D**


A mixture of **1a** (21 mg, 0.1 mmol), [{RuCl₂(*p*-cymene)}₂] (3 mg, 5.0 mol %), and CsOAc (19 mg, 0.1 mmol) was stirred in D₂O (3.0 mL, 95 °C) or CD₃OD (3.0 mL, 60 °C) under argon for 24 hours. The solvent was removed under and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 15-20% EtOAc in hexane as the eluant. The product did not show any H/D exchange.

2.5 General procedure for the synthesis of indolo[1,2-*a*]quinazolinones (**4aj'-al'**)

A mixture of **1a** (21 mg, 0.1 mmol), **2j-l** (0.1 mmol), [{RuCl₂(*p*-cymene)}₂] (3 mg, 5.0 mol %), and CsOAc (19 mg, 0.1 mmol) in *t*AmOH (3.0 mL) was stirred at 95 °C under open air for 3 hours. The solvent was removed under vacuo and the crude product obtained was

purified by silica gel (100-200 mesh) column chromatography using 20% EtOAc in hexane as the eluant to afford **4aj'-al'**.

2.6 Optimization of the reaction conditions for **3aa**^a (Table SI-1)



entry	catalyst	additive	solvent	3aa (%) ^b
1	[RuCl ₂ (PPh ₃) ₃]	Cu(OAc) ₂ .H ₂ O	<i>t</i> AmOH	0
2	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	Cu(OAc) ₂ .H ₂ O	<i>t</i> AmOH	38
3	Pd(OAc) ₂	Cu(OAc) ₂ .H ₂ O	<i>t</i> AmOH	0
4	[(Cp* <i>Rh</i> Cl ₂) ₂]	Cu(OAc) ₂ .H ₂ O	<i>t</i> AmOH	0
5	[Cp* <i>Ir</i> Cl ₂] ₂	Cu(OAc) ₂ .H ₂ O	<i>t</i> AmOH	0
6	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CuBr ₂	<i>t</i> AmOH	11
7	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	<i>t</i> AmOH	79
8	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	AgOAc	<i>t</i> AmOH	37
9	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	KOAc	<i>t</i> AmOH	31
10	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	1,4-dioxane	34
11	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	acetonitrile	62
12	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	DMF	41
13	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	toluene	30
14 ^c	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	<i>t</i> AmOH	51
15 ^d	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	CsOAc	<i>t</i> AmOH	77



^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), catalyst (5 mol %), additive (0.1 mmol) and *t*AmOH (3.0 mL) at 95 °C under air for 24 h. ^bIsolated yields. ^cCatalyst 2.5 mol %.


^dCatalyst 7.5 mol %.


References:

- (a) P. Singh, N. Kaur, P. Banerjee, *J. Org. Chem.* **2020**, *85*, 3393–3406. (b) W. Yang, R. Qiao, J. Chen, X. Huang, M. Liu, W. Gao, J. Ding, H. Wu, *J. Org. Chem.* **2015**, *80*,

Spectral and analytical data of compounds **3** and **4**


 <p>3aa</p>	<p>7,7-diphenylindolo[1,2-<i>a</i>]quinazolin-5(7<i>H</i>)-one (3aa): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol), which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3aa (30 mg, 79%). M.p.: 266-268 °C. UV-vis (CHCl₃) λ_{max} 325 nm, ε_{max} 3700. FTIR (CHCl₃, cm⁻¹) ν_{max} 1656, 1598, 1554. ¹H NMR (500 MHz, CDCl₃) δ 8.47 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 8.26 (d, <i>J</i> = 8.5 Hz, 1H), 8.04 (d, <i>J</i> = 8.2 Hz, 1H), 7.85 (t, <i>J</i> = 8.7 Hz, 1H), 7.56 (t, <i>J</i> = 8.0 Hz, 1H), 7.52 (t, <i>J</i> = 7.5 Hz, 1H), 7.43 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.34-7.25 (m, 10H). ¹³C NMR (125 MHz, CDCl₃) δ 170.4, 168.7, 141.6, 139.8, 137.7, 136.2, 133.8, 129.6, 128.7, 128.4, 127.7, 127.6, 126.5, 125.9, 119.4, 115.0, 113.7, 63.2. HRMS (+ESI) Calcd for C₂₇H₁₉N₂O [M+H]⁺: 387.1497; found: 387.1495. Anal. Calcd for C₂₇H₁₈N₂O: C, 83.92; H, 4.69; N, 7.25. Found: C, 84.06; H, 4.97; N, 7.38.</p>
 <p>3ab</p>	<p>7,7-bis(4-methoxyphenyl)indolo[1,2-<i>a</i>]quinazolin-5(7<i>H</i>)-one (3ab): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2b (24 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ab (28 mg, 63%). M.p.: 269-271 °C. UV-vis (CHCl₃) λ_{max} 330 nm, ε_{max} 9500. FTIR (CHCl₃, cm⁻¹) ν_{max} 1657, 1595, 1556, 1461. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (d, <i>J</i> = 8.0 Hz, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.83 (t, <i>J</i> = 7.0 Hz, 1H), 7.55 (t, <i>J</i> = 8.0 Hz, 1H), 7.50 (t, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 7.5 Hz, 1H), 7.34 (t, <i>J</i> = 7.5 Hz, 1H), 7.24 (d, <i>J</i> = 8.5 Hz, 4H), 6.80 (d, <i>J</i> = 8.5 Hz, 4H), 3.76 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 171.0, 168.8, 159.0, 139.6, 137.8, 136.9, 133.8,</p>

	<p>133.7, 129.8, 129.6, 128.5, 127.4, 126.4, 125.9, 119.4, 114.9, 113.7, 113.6, 62.0, 55.2. HRMS (+ESI) Calcd for C₂₉H₂₃N₂O₃ [M+H]⁺: 447.1709; found: 447.1703. Anal. Calcd for C₂₉H₂₂N₂O₃: C, 78.01; H, 4.97; N, 6.27. Found: C, 78.21; H, 4.90; N, 6.36.</p>
 <p style="text-align: center;">3ac</p>	<p>7,7-di-<i>p</i>-tolylindolo[1,2-<i>a</i>]quinazolin-5(7<i>H</i>)-one (3ac): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2c (21 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford a white solid of 3ac (28 mg, 68%). M.p.: 266-268 °C. UV-vis (CHCl₃) λ_{max} 330 nm, ε_{max} 4600. FTIR (CHCl₃, cm⁻¹) ν_{max} 1656, 1594, 1555, 1460, 743. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 8.24 (d, <i>J</i> = 8.5 Hz, 1H), 8.01 (d, <i>J</i> = 8.2 Hz, 1H), 7.82 (t, <i>J</i> = 8.6 Hz, 1H), 7.55 (t, <i>J</i> = 7.5 Hz, 1H), 7.50 (t, <i>J</i> = 8.0 Hz, 1H), 7.42 (d, <i>J</i> = 7.5 Hz, 1H), 7.33 (t, <i>J</i> = 7.5 Hz, 1H), 7.20 (d, <i>J</i> = 8.5 Hz, 4H), 7.08 (d, <i>J</i> = 8.1 Hz, 4H), 2.30 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 171.0, 169.0, 140.1, 139.0, 138.1, 137.7, 137.0, 134.0, 129.9, 129.4, 128.9, 128.8, 127.8, 126.7, 126.2, 119.8, 115.2, 113.9, 63.0, 21.2. HRMS (+ESI) Calcd for C₂₉H₂₃N₂O [M+H]⁺: 415.1810; found: 415.1817. Anal. Calcd for C₂₉H₂₂N₂O: C, 84.03; H, 5.35; N, 6.76. Found: C, 83.93; H, 5.18; N, 6.51.</p>







7,7-bis(4-fluorophenyl)indolo[1,2-a]quinazolin-5(7H)-one



(3ad): The title compound was prepared by following the general procedure **2.2** from indazolone **1a** (21 mg, 0.1 mmol) and alkyne **2d** (21 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of **3ad** (24 mg, 57% yield). M.p.: 145–147 °C. UV-vis (CHCl₃) λ_{\max} 323 nm, ϵ_{\max} 10200. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1656, 1596, 1553, 741. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (dd, J = 8.0, 1.4 Hz, 1H), 8.25 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.88-7.84 (m, 1H), 7.58 (t, J = 7.0 Hz, 1H), 7.56-7.53 (m, 1H), 7.40-7.35 (m, 2H), 7.31-7.27 (m, 4H), 7.00-6.95 (m, 4H). ¹³C NMR (125 MHz, CDCl₃) δ 169.3 (d, J = 203 Hz), 162.2 (d, J = 246.3 Hz), 139.7, 137.6, 137.2 (d, J = 3.8 Hz), 135.8, 134.0, 130.4 (d, J = 8.8 Hz), 129.7, 129.1, 127.3, 126.7, 126.1, 122.3, 119.4, 115.4 (d, J = 21.3 Hz), 113.8, 62.0. HRMS (+ESI) Calcd for C₂₇H₁₇F₂N₂O [M+H]⁺: 423.1309; found: 423.1313. Anal. Calcd for C₂₇H₁₆F₂N₂O: C, 76.77; H, 3.82; N, 6.63. Found: C, 76.92; H, 3.97; N, 6.45.







7,7-di-*m*-tolyindolo[1,2-a]quinazolin-5(7H)-one (3ae): The title compound was prepared by following the general procedure **2.2** from indazolone **1a** (21 mg, 0.1 mmol) and alkyne **2e** (21 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford white solid of **3ae** (27 mg, 65%). M.p.: 196–198 °C. UV-vis (CHCl₃) λ_{\max} 330 nm, ϵ_{\max} 3800. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1656, 1598, 1552, 743. ¹H NMR (500 MHz, CDCl₃) δ 8.47 (dd, J = 7.9, 1.5 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.84 (t, J = 8.7 Hz, 1H), 7.56 (t, J = 7.0 Hz, 1H), 7.51 (t, J = 7.0 Hz, 1H), 7.42 (dd, J = 7.6, 1.1 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 7.20-7.05 (m, 8H), 2.26 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 170.5, 168.8, 141.5, 139.7, 138.0, 137.8, 136.5, 133.8, 129.6, 129.2, 128.6, 128.5, 128.2, 127.5, 126.4, 125.9, 125.9, 119.5, 115.0, 113.6, 63.2, 21.5. HRMS (+ESI) Calcd for C₂₉H₂₃N₂O [M+H]⁺: 415.1810; found:



	<p>415.1803. Anal. Calcd for C₂₉H₂₂N₂O: C, 84.03; H, 5.35; N, 6.76. Found: C, 84.08; H, 5.60; N, 6.89.</p>
 <p>3af</p>	<p>7-phenyl-7-(p-tolyl)indolo[1,2-a]quinazolin-5(7H)-one (3af): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2f (19 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3af (27 mg, 67%). M.p.: 255–257 °C. UV-vis (CHCl₃) λ_{max} 320 nm, ε_{max} 3400. FTIR (CHCl₃, cm⁻¹) ν_{max} 1659, 1598, 1554, 740. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, <i>J</i> = 7.9 Hz, 1H), 8.25 (d, <i>J</i> = 8.5 Hz, 1H), 8.03 (d, <i>J</i> = 8.2 Hz, 1H), 7.83 (t, <i>J</i> = 7.0 Hz, 1H), 7.55 (t, <i>J</i> = 7.0 Hz, 1H), 7.51 (t, <i>J</i> = 8.5 Hz, 1H), 7.42 (d, <i>J</i> = 7.5 Hz, 1H), 7.35 (d, <i>J</i> = 7.5 Hz, 1H), 7.33-7.24 (m, 5H), 7.23 (d, <i>J</i> = 9.5 Hz, 2H), 7.09 (d, <i>J</i> = 9.4 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.7, 168.9, 141.9, 139.9, 138.6, 137.9, 137.7, 136.5, 133.9, 129.7, 129.2, 128.8, 128.8, 128.5, 127.7, 127.6, 126.6, 126.0, 119.6, 115.1, 113.8, 63.1, 21.1. HRMS (+ESI) Calcd for C₂₈H₂₁N₂O [M+H]⁺: 401.1654; found: 401.1473. Anal. Calcd for C₂₈H₂₀N₂O: C, 83.98; H, 5.03; N, 7.00. Found: C, 83.80; H, 4.92; N, 6.83.</p>
 <p>3ag</p>	<p>7-(4-fluorophenyl)-7-(p-tolyl)indolo[1,2-a]quinazolin-5(7H)-one (3ag): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2g (21 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ag (27 mg, 64%). M.p.: 263–265°C. UV-vis (CHCl₃) λ_{max} 330 nm, ε_{max} 3300. FTIR (CHCl₃, cm⁻¹) ν_{max} 1652, 1598, 1557. ¹H NMR (500 MHz, CDCl₃) δ 8.47 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 8.25 (d, <i>J</i> = 8.5 Hz, 1H), 8.03 (d, <i>J</i> = 8.2 Hz, 1H), 7.84 (t, <i>J</i> = 8.7 Hz, 1H), 7.56 (t, <i>J</i> = 8.0 Hz, 1H), 7.52 (t, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 7.5 Hz, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.32-7.26 (m, 2H), 7.19 (d, <i>J</i> = 8.3 Hz, 2H), 7.09 (d, <i>J</i> = 8.1 Hz, 2H), 6.97 (t, <i>J</i> = 8.7 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.4,</p>


	<p>168.6, 162.1 (d, $J = 246.1$ Hz), 161.2, 139.7, 138.5, 137.7 (d, $J = 3.8$ Hz), 137.4 (d, $J = 3.3$ Hz), 136.2, 133.8, 130.5 (d, $J = 8.8$ Hz), 129.6, 129.2, 128.8, 128.4, 127.4, 126.5, 126.0, 119.4, 115.3 (d, $J = 21.3$ Hz), 115.0 (d, $J = 23.8$ Hz), 115.0, 113.7, 62.3, 20.9. HRMS (+ESI) Calcd for $C_{28}H_{20}FN_2O$ $[M+H]^+$: 419.1560; found: 419.1580. Anal. Calcd for $C_{28}H_{19}FN_2O$: C, 80.37; H, 4.58; N, 6.69. Found: C, 80.43; H, 4.66; N, 6.74.</p>
 <p>3ah</p>	<p>7-(3-chlorophenyl)-7-(4-fluorophenyl)indolo[1,2-a]quinazolin-5(7H)-one (3ah): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2h (23 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ah (21 mg, 48%). M.p.: 156–159 °C. UV-vis ($CHCl_3$) λ_{max} 330 nm, ϵ_{max} 4000. FTIR ($CHCl_3$, cm^{-1}) ν_{max} 1656, 1596, 1554. 1H NMR (500 MHz, $CDCl_3$) δ 8.45 (d, $J = 8.0$ Hz, 1H), 8.34 (s, 1H), 8.18 (d, $J = 8.5$ Hz, 1H), 8.03 (d, $J = 8.2$ Hz, 1H), 7.83 (t, $J = 7.9$ Hz, 1H), 7.60–7.50 (m, 2H), 7.37 (t, $J = 7.5$ Hz, 1H), 7.29–7.17 (m, 7H), 7.04 (d, $J = 7.6$ Hz, 1H). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.3, 168.6, 162.7 (d, $J = 245.0$ Hz), 141.3, 139.4, 137.8, 133.9 (d, $J = 12.5$ Hz), 133.3 (d, $J = 2.5$ Hz), 131.7, 131.1, 129.6, 129.1, 126.2, 126.5, 126.4, 125.6, 119.3, 116.3, 115.2, 113.3, 61.9. HRMS (+ESI) Calcd for $C_{27}H_{17}ClFN_2O$ $[M+H]^+$: 439.1013; found: 439.1017. Anal. Calcd for $C_{27}H_{16}ClFN_2O$: C, 73.89; H, 3.67; N, 6.38. Found: C, 74.06; H, 3.54; N, 6.61.</p>
 <p>3ai</p>	<p>7-phenyl-7-(thiophen-2-yl)indolo[1,2-a]quinazolin-5(7H)-one (3ai): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2i (20 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford light yellow solid of 3ai (21 mg, 51%). M.p.: 208–210°C. UV-vis ($CHCl_3$) λ_{max} 315 nm, ϵ_{max} 3200. FTIR ($CHCl_3$, cm^{-1}) ν_{max} 1656, 1598, 1554. 1H NMR (500 MHz, $CDCl_3$) δ 8.48 (dd, $J = 8.0, 1.4$</p>


	<p>Hz, 1H), 8.25 (d, $J = 8.5$ Hz, 1H), 8.02 (d, $J = 8.2$ Hz, 1H), 7.85 (t, $J = 8.7$Hz, 1H), 7.60-7.52 (m, 3H), 7.38 (t, $J = 7.6$ Hz, 1H), 7.29-7.26 (m, 1H), 7.21-7.16 (m, 3H), 7.08 (d, $J = 8.1$ Hz, 2H), 6.97-6.95 (m, 1H), 2.30 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.9, 168.7, 143.8, 139.8, 138.4, 138.0, 137.8, 136.6, 134.0, 129.8, 129.2, 128.3, 127.9, 127.3, 126.7, 126.66, 126.2, 126.0, 119.6, 115.1, 113.8, 60.2, 21.1. HRMS (+ESI) Calcd for $\text{C}_{26}\text{H}_{19}\text{N}_2\text{OS}$ $[\text{M}+\text{H}]^+$: 407.1218; found: 407.1081. Anal. Calcd for $\text{C}_{26}\text{H}_{18}\text{N}_2\text{OS}$: C, 76.82; H, 4.46; N, 6.89. Found: C, 76.67; H, 4.41; N, 6.94.</p>
 <p>3ba</p>	<p>3-methyl-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3ba): The title compound was prepared by following the general procedure 2.2 from indazolone 1b (22 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ba (27 mg, 68%). M.p.: 301–303 °C. UV-vis (CHCl_3) λ_{max} 335 nm, ϵ_{max} 3850. FTIR (CHCl_3, cm^{-1}) ν_{max} 1656, 1591, 1556. ^1H NMR (500 MHz, CDCl_3) δ 8.28 (d, $J = 1.0$ Hz, 1H), 8.15 (d, $J = 8.6$ Hz, 1H), 8.01 (d, $J = 8.2$ Hz, 1H), 7.64 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.55-7.48 (m, 1H), 7.43 (dd, $J = 7.6, 1.0$ Hz, 1H), 7.37-7.27 (m, 11H), 2.51 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 168.9, 141.8, 140.1, 136.8, 136.4, 135.8, 135.0, 129.3, 128.86, 128.8, 128.5, 127.8, 127.6, 125.9, 119.4, 115.0, 113.7, 63.3, 21.1. HRMS (+ESI) Calcd for $\text{C}_{28}\text{H}_{21}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 401.1654; found: 401.1667. Anal. Calcd for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{O}$: C, 83.98; H, 5.03; N, 7.00. Found: C, 83.73; H, 5.18; N, 7.36.</p>
 <p>3ca</p>	<p>3-methoxy-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3ca): The title compound was prepared by following the general procedure 2.2 from indazolone 1c (24 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ca (25 mg, 60%). M.p.: 295–297°C. UV-vis (CHCl_3) λ_{max} 340 nm, ϵ_{max} 4250. FTIR (CHCl_3, cm^{-1}) ν_{max} 1656, 1596,</p>

	<p>1561. ^1H NMR (500 MHz, CDCl_3) δ 8.21 (d, $J = 9.3$ Hz, 1H), 8.00 (d, $J = 8.3$ Hz, 1H), 7.89 (d, $J = 3.1$ Hz, 1H), 7.53-7.49 (m, 1H), 7.45-7.41 (m, 2H), 7.37-7.24 (m, 11H), 3.94 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.6, 169.0, 158.2, 141.9, 140.2, 136.7, 132.2, 129.1, 129.0, 128.7, 128.0, 127.8, 126.2, 123.9, 121.3, 117.0, 113.8, 109.6, 63.5, 56.2. HRMS (+ESI) Calcd for $\text{C}_{28}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 417.1603; found: 417.1580. Anal. Calcd for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{O}_2$: C, 80.75; H, 4.84; N, 6.73. Found: C, 80.88; H, 4.97; N, 6.92.</p>
 <p style="text-align: center;">3da</p>	<p>3-chloro-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3da): The title compound was prepared by following the general procedure 2.2 from indazolone 1d (24 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3da (24 mg, 57%). M.p.: 315-317 °C. UV-vis (CHCl_3) λ_{max} 328 nm, ϵ_{max} 2350. FTIR (CHCl_3, cm^{-1}) ν_{max} 1657, 1589, 1545. ^1H NMR (500 MHz, CDCl_3) δ 8.45 (d, $J = 2.5$ Hz, 1H), 8.21 (d, $J = 9.0$ Hz, 1H), 7.97 (d, $J = 8.0$ Hz, 1H), 7.79 (dd, $J = 9.0$ Hz, 2.5 Hz, 1H), 7.53 (t, $J = 7.5$ Hz, 1H), 7.44 (d, $J = 7.5$ Hz, 1H), 7.37 (t, $J = 7.5$ Hz, 1H), 7.32-7.25 (m, 10H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.7, 167.6, 141.5, 139.6, 136.3, 136.2, 134.0, 132.5, 129.2, 128.9, 128.8, 128.6, 127.9, 127.8, 127.5, 127.3, 126.3, 120.9, 116.7, 113.6, 63.3. HRMS (+ESI) Calcd for $\text{C}_{27}\text{H}_{18}\text{ClN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 421.1108; found: 421.1095. Anal. Calcd for $\text{C}_{27}\text{H}_{17}\text{ClN}_2\text{O}$: C, 77.05; H, 4.07; N, 6.66. Found: C, 76.83; H, 3.86; N, 6.92.</p>
 <p style="text-align: center;">3ea</p>	<p>3-bromo-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one(3ea): The title compound was prepared by following the general procedure 2.2 from indazolone 1e (29 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ea (27 mg, 58%). M.p.: 325-327°C. UV-vis (CHCl_3) λ_{max} 330 nm, ϵ_{max} 3300. FTIR (CHCl_3, cm^{-1}) ν_{max} 1655, 1590. ^1H</p>

	<p>NMR (500 MHz, CDCl₃) δ 8.61 (d, <i>J</i> = 2.4 Hz, 1H), 8.15 (d, <i>J</i> = 9.0 Hz, 1H), 7.96 (d, <i>J</i> = 8.3 Hz, 1H), 7.92 (dd, <i>J</i> = 9.0, 2.4 Hz, 1H), 7.53 (t, <i>J</i> = 9.0 Hz, 1H), 7.44 (d, <i>J</i> = 7.5 Hz, 1H), 7.37 (t, <i>J</i> = 7.5 Hz, 1H), 7.33-7.27 (m, 10H). ¹³C NMR (125 MHz, CDCl₃) δ 170.9, 167.7, 141.7, 139.7, 137.1, 136.8, 136.5, 132.5, 129.2, 129.0, 128.8, 128.1, 128.0, 126.5, 121.2, 120.2, 117.1, 113.9, 63.7. HRMS (+ESI) Calcd for C₂₇H₁₈BrN₂O [M+H]⁺: 465.0602; found: 465.0428. Anal. Calcd for C₂₇H₁₇BrN₂O: C, 69.69; H, 3.68; N, 6.02. Found: C, 69.90; H, 3.49; N, 5.80.</p>
 <p>3fa</p>	<p>1-methyl-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3fa): The title compound was prepared by following the general procedure 2.2 from indazolone 1f (22 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford light brown solid of 3fa (26 mg, 65%). M.p.: 246–248 °C. UV-vis (CHCl₃) λ_{max} 334 nm, ε_{max} 1500. FTIR (CHCl₃, cm⁻¹) ν_{max} 1656, 1598, 1589. ¹H NMR (500 MHz, CDCl₃) δ 8.47 (d, <i>J</i> = 7.9 Hz, 1H), 8.27 (d, <i>J</i> = 8.6 Hz, 1H), 7.87-7.84 (m, 2H), 7.56 (t, <i>J</i> = 6.7 Hz, 1H), 7.33-7.27 (m, 11H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 2.54 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.7, 168.7, 141.7, 139.9, 139, 137.8, 133.8, 133.3, 129.6, 128.7, 128.7, 128.4, 127.6, 127.1, 126.6, 126.4, 115.1, 114.4, 63.0, 22.0. HRMS (+ESI) Calcd for C₂₈H₂₁N₂O [M+H]⁺:401.1654; found: 401.1659. Anal. Calcd for C₂₈H₂₀N₂O: C, 83.98; H, 5.03; N, 7.00. Found: C, 84.26; H, 5.07; N, 7.28.</p>
 <p>3ga</p>	<p>9-methoxy-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3ga): The title compound was prepared by following the general procedure 2.2 from indazolone 1g (24 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford off white solid of 3ga (24 mg, 58%). M.p.: 289–291 °C. UV-vis (CHCl₃) λ_{max} 338 nm, ε_{max} 1250. FTIR (CHCl₃, cm⁻¹) ν_{max} 1656, 1598, 1552. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (dd, <i>J</i> = 7.9, 1.4 Hz,</p>


	<p>1H), 8.19 (d, $J = 8.5$ Hz, 1H), 7.94 (d, $J = 8.9$ Hz, 1H), 7.84-7.80 (m, 1H), 7.56-7.52 (m, 1H), 7.35-7.27 (m, 10H), 7.00 (dd, $J = 8.9, 2.7$ Hz, 1H), 6.95 (d, $J = 2.7$ Hz, 1H), 3.82 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.1, 168.7, 157.7, 141.6, 138.0, 137.6, 133.7, 133.2, 129.6, 128.7, 128.4, 127.7, 126.3, 119.4, 114.7, 114.4, 113.8, 113.2, 63.5, 55.7. HRMS (+ESI) Calcd for $\text{C}_{28}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 417.1603; found: 417.1590. Anal. Calcd for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{O}_2$: C, 80.75; H, 4.84; N, 6.73. Found: C, 80.71; H, 4.83; N, 6.51.</p>
 <p>3ha</p>	<p>9-chloro-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3ha): The title compound was prepared by following the general procedure 2.2 from indazolone 1h (24 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford off white solid of 3ha (22 mg, 53%). M.p.: 305–307 °C. UV-vis (CHCl_3) λ_{max} 340 nm, ϵ_{max} 1050. FTIR (CHCl_3, cm^{-1}) ν_{max} 1656, 1596, 1552. ^1H NMR (500 MHz, CDCl_3) δ 8.47 (dd, $J = 7.9, 1.5$ Hz, 1H), 8.16 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 8.7$ Hz, 1H), 7.87-7.82 (m, 1H), 7.57 (t, $J = 7.6$ Hz, 1H), 7.49 (dd, $J = 8.7, 2.2$ Hz, 1H), 7.38 (d, $J = 2.2$ Hz, 1H), 7.34-7.27 (m, 10H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 168.4, 140.9, 138.3, 138.1, 137.4, 133.9, 131.5, 129.8, 128.8, 128.6, 128.6, 128.0, 127.7, 126.7, 119.4, 114.7, 114.5, 63.2. HRMS (+ESI) Calcd for $\text{C}_{27}\text{H}_{18}\text{ClN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 421.1108; found: 421.1095. Anal. Calcd for $\text{C}_{27}\text{H}_{17}\text{ClN}_2\text{O}$: C, 77.05; H, 4.07; N, 6.66. Found: C, 76.82; H, 4.18; N, 6.40.</p>
 <p>3ia</p>	<p>9,10-dimethyl-7,7-diphenylindolo[1,2-a]quinazolin-5(7H)-one (3ia): The title compound was prepared by following the general procedure 2.2 from indazolone 1i (24 mg, 0.1 mmol) and alkyne 2a (18 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 3ia (26 mg, 64%). M.p.: 277–279 °C. UV-vis (CHCl_3) λ_{max} 333 nm, ϵ_{max} 950. FTIR (CHCl_3, cm^{-1}) ν_{max} 1657, 1601, 1547.</p>

	<p>^1H NMR (500 MHz, CDCl_3) δ 8.46 (dd, $J = 8.0, 1.4$ Hz, 1H), 8.26 (d, $J = 8.5$ Hz, 1H), 7.85-7.82 (m, 1H), 7.81 (s, 1H), 7.55 (t, $J = 7.0$ Hz, 1H), 7.34-7.25 (m, 10H), 7.15 (s, 1H), 2.44 (s, 3H), 2.30 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.5, 168.8, 141.9, 137.9, 137.8, 137.3, 134.6, 133.7, 133.6, 129.5, 128.7, 128.3, 128.2, 127.5, 126.3, 119.4, 115.0, 114.8, 63.1, 20.6, 19.8. HRMS (+ESI) Calcd for $\text{C}_{29}\text{H}_{23}\text{N}_2\text{O}[\text{M}+\text{H}]^+$: 415.1810; found: 415.1812. Anal. Calcd for $\text{C}_{29}\text{H}_{22}\text{N}_2\text{O}$: C, 84.03; H, 5.35; N, 6.76. Found: C, 84.34; H, 5.24; N, 6.50.</p>
 <p style="text-align: center;">4aj</p>	<p>12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-a]indazol-10-one (4aj): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2j (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford a brown thick liquid of 4aj (21 mg, 62%). UV-vis (CHCl_3) λ_{max} 300 nm, ϵ_{max} 13850. FTIR (CHCl_3, cm^{-1}) ν_{max} 1719, 1656, 1608, 1501. ^1H NMR (500 MHz, CDCl_3) δ 7.87 (d, $J = 7.9$ Hz, 1H), 7.61-7.58 (m, 1H), 7.49 (d, $J = 8.3$ Hz, 1H), 7.38-7.34 (m, 1H), 7.26-7.28 (m, 1H), 7.20-7.14 (m, 2H), 7.06-7.03 (m, 1H), 4.04 (d, $J = 17.4$ Hz, 1H), 3.26 (d, $J = 17.3$ Hz, 1H), 2.58-2.52 (m, 1H), 2.42-2.26 (m, 2H), 2.01-1.94 (m, 1H), 1.27-1.10 (m, 1H), 1.06-0.98 (m, 1H), 0.83 (t, $J = 7.3$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.8, 159.0, 138.2, 136.7, 134.7, 131.8, 128.9, 124.3, 122.5, 122.1, 120.9, 119.5, 109.8, 107.9, 67.4, 47.2, 40.9, 36.4, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 335.1759; found: 335.1758. Anal. Calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_2$: C, 75.42; H, 6.63; N, 8.38. Found: C, 75.77; H, 6.41; N, 8.05.</p>





4bj



8-methyl-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-*a*]indazol-10-one (4bj): The title compound was prepared by following the general procedure **2.2** from indazolone **1b** (22 mg, 0.1 mmol) and alkyne **2j** (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford a yellow gummy liquid of **4bj** (22 mg, 63%). UV-vis (CHCl₃) λ_{\max} 298 nm, ϵ_{\max} 3250. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1719, 1656, 1500. NMR (400 MHz,) δ 7.64 (s, 1H), 7.40 (d, *J* = 3.9 Hz, 2H), 7.38-7.31 (m, 1H), 7.25-7.21 (m, 1H), 7.18 (d, *J* = 7.5 Hz, 1H), 7.02 (t, *J* = 7.5 Hz, 1H), 4.03 (d, *J* = 17.3 Hz, 1H), 3.24 (d, *J* = 17.3 Hz, 1H), 2.68-2.46 (m, 1H), 2.43 (s, 3H), 2.42-2.24 (m, 2H), 1.98-1.80 (m, 1H), 1.25-1.17 (m, 1H), 1.05-0.98 (m, 1H), 0.83 (t, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 207.1, 159.3, 142.0, 136.7, 134.8, 131.0, 127.9, 124.8, 122.5, 122.3, 119.8, 111.2, 107.9, 68.1, 48.5, 42.4, 37.5, 21.2, 18.1, 13.8, 7.4. HRMS (+ESI) Calcd for C₂₂H₂₅N₂O₂ [M+H]⁺: 349.1916; found: 349.1920. Anal. Calcd for C₂₂H₂₄N₂O₂: C, 75.83; H, 6.94; N, 8.04. Found: C, 75.49; H, 7.27; N, 8.16.






4dj


8-chloro-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-*a*]indazol-10-one (4dj): The title compound was prepared by following the general procedure **2.2** from indazolone **1d** (24 mg, 0.1 mmol) and alkyne **2j** (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford yellow gummy liquid of **4dj** (20 mg, 54%). UV-vis (CHCl₃) λ_{\max} 304 nm, ϵ_{\max} 4800. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1719, 1656, 1493. ¹H NMR (500 MHz, CDCl₃) δ 7.83 (d, *J* = 2.0 Hz, 1H), 7.54 (dd, *J* = 8.7, 2.0 Hz, 1H), 7.43 (dd, *J* = 8.7, 0.4 Hz, 1H), 7.38-7.34 (m, 1H), 7.23 (d, *J* = 7.8 Hz, 1H), 7.19-7.17 (m, 1H), 7.08-7.05 (m, 1H), 4.06 (d, *J* = 17.6 Hz, 1H), 3.22 (d, *J* = 17.6 Hz, 1H), 2.53-2.47 (m, 1H), 2.41-2.24 (m, 2H), 1.98-1.92 (m, 1H), 1.30-1.20 (m, 1H), 1.05-0.99 (m, 1H), 0.83 (t, *J* = 7.7 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 206.8, 158.1, 136.6, 136.4, 134.7, 132.2, 129.01, 126.5, 123.9, 122.9, 122.0, 120.5, 110.9,



	<p>107.9, 67.6, 46.8, 41.0, 36.4, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for C₂₁H₂₂ClN₂O₂ [M+H]⁺: 369.1369; found: 369.1361. Anal. Calcd for C₂₁H₂₁ClN₂O₂: C, 68.38; H, 5.74; N, 7.59. Found: C, 68.47; H, 5.71; N, 7.90.</p>
 <p style="text-align: center;">4ej</p>	<p>8-bromo-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-a]indazol-10-one (4ej): The title compounds was prepared by following the general procedure 2.2 from indazolone 1e (29 mg, 0.1 mmol) and alkyne 2j (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford yellow gummy liquid of 3ej (24 mg, 59%). UV-vis (CHCl₃) λ_{max} 304 nm, ε_{max} 2200. FTIR (CHCl₃, cm⁻¹) ν_{max} 1719, 1659, 1603, 1500, 1468. ¹H NMR (500 MHz, CDCl₃) δ 7.98 (d, <i>J</i> = 1.9 Hz, 1H), 7.66 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 7.40-7.38 (m, 1H), 7.35 (d, <i>J</i> = 7.7 Hz, 1H), 7.23 (d, <i>J</i> = 7.9 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (t, <i>J</i> = 7.5 Hz, 1H), 4.05 (d, <i>J</i> = 17.5 Hz, 1H), 3.22 (d, <i>J</i> = 17.5 Hz, 1H), 2.53-2.47 (m, 1H), 2.42–2.23 (m, 2H), 1.98–1.94 (m, 1H), 1.30-1.18 (m, 1H), 1.10-0.86 (m, 1H), 0.83 (t, <i>J</i> = 7.3 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 206.8, 157.8, 136.8, 136.4, 134.8, 134.7, 129.0, 127.0, 122.9, 122.0, 120.9, 113.5, 111.2, 108.0, 67.6, 46.8, 41.0, 36.4, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for C₂₁H₂₂BrN₂O₂ [M+H]⁺: 413.0864; found: 413.0863.</p>
 <p style="text-align: center;">4fj</p>	<p>2-methyl-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-a]indazol-10-one (4fj): The title compound was prepared by following the general procedure 2.2 from indazolone 1f (22 mg, 0.1 mmol) and alkyne 2j (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford yellow gummy liquid of 4fj (22 mg, 64%). UV-vis (CHCl₃) λ_{max} 300 nm, ε_{max} 9650. FTIR (CHCl₃, cm⁻¹) ν_{max} 1719, 1656, 1502. ¹H NMR (500 MHz, CDCl₃) δ 7.86 (d, <i>J</i> = 7.9 Hz, 1H), 7.58 (t, <i>J</i> = 7.7 Hz, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 7.10–7.05 (m, 2H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 4.00 (d, <i>J</i> = 17.3 Hz, 1H), 3.23 (d, <i>J</i> = 17.2 Hz, 1H), 2.57-2.51 (m, 1H),</p>



	<p>2.37 (s, 3H), 2.37-2.26 (m, 2H), 2.00-1.93 (m, 1H), 1.31-1.14 (m, 1H), 1.06-1.00 (m, 1H), 0.84-0.80 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 206.9, 158.9, 139.2, 138.0, 136.7, 131.8, 131.7, 124.2, 123.3, 121.9, 120.8, 119.4, 109.7, 108.7, 67.4, 47.2, 40.8, 36.4, 21.6, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for C₂₂H₂₅N₂O₂ [M+H]⁺: 349.1916; found: 349.1918.</p>
 <p>4gj</p>	<p>2,3-dimethyl-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-a]indazol-10-one (4gj): The title compound was prepared by following the general procedure 2.2 from indazolone 1g (24 mg, 0.1 mmol) and alkyne 2j (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford gummy liquid of 4gj (18 mg, 51%). UV-vis (CHCl₃) λ_{max} 300 nm, ε_{max} 3700. FTIR (CHCl₃, cm⁻¹) ν_{max} 1719, 1654, 1610, 1500. ¹H NMR (500 MHz, CDCl₃) δ 7.85 (dd, <i>J</i> = 7.8, 0.8 Hz, 1H), 7.59-7.56 (m, 1H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 7.15-7.10 (m, 1H), 7.06 (s, 1H), 6.94 (s, 1H), 3.99 (d, <i>J</i> = 17.2 Hz, 1H), 3.22 (d, <i>J</i> = 17.2 Hz, 1H), 2.57-2.50 (m, 1H), 2.40-2.30 (m, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.97-1.91 (m, 1H), 1.25-1.15 (m, 1H), 1.15-0.94 (m, 1H), 0.85-0.80 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 207.0, 158.9, 138.0, 137.4, 134.8, 132.0, 131.6, 130.8, 124.2, 123.1, 120.5, 119.1, 109.6, 109.2, 67.4, 47.3, 40.8, 36.4, 20.2, 19.7, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for C₂₃H₂₇N₂O₂ [M+H]⁺: 363.2072; found: 363.2073. Anal. Calcd for C₂₃H₂₆N₂O₂: C, 76.21; H, 7.23; N, 7.73. Found: C, 76.04; H, 7.29; N, 7.62.</p>
 <p>4ij</p>	<p>2-chloro-12-(2-oxobutyl)-12-propyl-10H,12H-indazolo[1,2-a]indazol-10-one (4ij): The title compound was prepared by following the general procedure 2.2 from indazolone 1i (24 mg, 0.1 mmol) and alkyne 2j (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford light yellow solid of 4ij (18 mg, 50%). UV-vis (CHCl₃) λ_{max} 300 nm, ε_{max} 3450. FTIR (CHCl₃, cm⁻¹) ν_{max} 1720, 1653, 1500. M.p.: 172–174 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.85 (d, <i>J</i></p>




	<p>= 7.7 Hz, 1H), 7.60 (t, $J = 7.3$ Hz, 1H), 7.45 (d, $J = 8.2$ Hz, 1H), 7.32 (d, $J = 8.1$ Hz, 1H), 7.25-7.13 (m, 3H), 4.09 (d, $J = 17.7$ Hz, 1H), 3.20 (d, $J = 17.9$ Hz, 1H), 2.49-2.33 (m, 3H), 1.92 (t, $J = 12.7$ Hz, 1H), 1.30-1.10 (m, 1H), 1.10-1.00 (m, 1H), 0.89-0.83 (m, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.6, 159.3, 138.5, 136.9, 135.6, 132.0, 128.9, 127.6, 124.4, 122.4, 121.4, 119.5, 109.7, 108.6, 67.3, 46.9, 41.1, 36.2, 16.8, 13.6, 7.2. HRMS (+ESI) Calcd for $\text{C}_{21}\text{H}_{22}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 369.1369; found: 369.1367. Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{ClN}_2\text{O}_2$: C, 68.38; H, 5.74; N, 7.59. Found: C, 68.65; H, 5.40; N, 7.78.</p>
 <p>4ak</p>	<p>12-butyl-12-(2-oxopentyl)-10H,12H-indazolo[1,2-a]indazol-10-one (4ak): The title compound was prepared by following the general procedure 2.2 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2k (14 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford light brown solid of 4ak (25 mg, 63%). UV-vis (CHCl_3) λ_{max} 300 nm, ϵ_{max} 3300. FTIR (CHCl_3, cm^{-1}) ν_{max} 1718, 1656, 1605, 1500. ^1H NMR (500 MHz, CDCl_3) δ 7.87 (d, $J = 7.9$ Hz, 1H), 7.59 (t, $J = 7.2$ Hz, 1H), 7.50 (d, $J = 9.3$ Hz, 1H), 7.36 (t, $J = 7.6$ Hz, 1H), 7.26 (d, $J = 6.3$ Hz, 1H), 7.19 (d, $J = 8.1$ Hz, 1H), 7.16 (t, $J = 7.1$ Hz, 1H), 7.05 (t, $J = 7.5$ Hz, 1H), 4.04 (d, $J = 17.4$ Hz, 1H), 3.23 (d, $J = 17.4$ Hz, 1H), 2.60-2.50 (m, 1H), 2.31-2.20 (m, 2H), 2.06-1.95 (m, 1H), 1.42-1.32 (m, 2H), 1.28-1.17 (m, 2H), 1.02-0.90 (m, 2H), 0.77 (t, $J = 6.9$ Hz, 3H), 0.71 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.5, 159.0, 138.3, 136.8, 134.7, 131.8, 128.9, 124.3, 122.5, 122.1, 120.1, 119.5, 109.8, 107.9, 67.4, 47.5, 45.2, 38.6, 25.5, 22.3, 16.6, 13.8, 13.3. HRMS (+ESI) Calcd for $\text{C}_{23}\text{H}_{27}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 363.2072; found: 363.2075. Anal. Calcd for $\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}_2$: C, 76.21; H, 7.23; N, 7.73. Found: C, 75.89; H, 7.01; N, 7.74.</p>



 <p style="text-align: center;">4aj'</p>	<p>(E)-6a-propyl-7-propylidene-6a,7-dihydroindolo[1,2-a]quinazolin-5(6H)-one (4aj'): The title compound was prepared by following the general procedure 2.5 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2j' (11 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford a yellow thick gum of 4aj' (10 mg, 33%). UV-vis (CHCl₃) λ_{\max} 296 nm, ϵ_{\max} 3850. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1663, 1596, 1491. ¹H NMR (500 MHz, CDCl₃) δ 8.09 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.64-7.59 (m, 1H), 7.58 (d, <i>J</i> = 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (t, <i>J</i> = 7.7 Hz, 1H), 7.20-7.14 (m, 2H), 6.95-6.89 (m, 1H), 6.31 (s, 1H), 5.70 (t, <i>J</i> = 7.1 Hz, 1H), 2.61 (pentate, <i>J</i> = 7.4 Hz, 2H), 2.17-2.02 (m, 1H), 1.77-1.72 (m, 1H), 1.23 (t, <i>J</i> = 7.5 Hz, 3H), 1.19-1.09 (m, 2H), 0.75 (t, <i>J</i> = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 162.2, 148.4, 139.9, 138.0, 133.4, 129.4, 128.9, 126.3, 126.0, 125.3, 123.4, 122.3, 122.1, 120.7, 107.6, 80.2, 42.1, 22.0, 17.6, 14.0, 13.8. HRMS (+ESI) Calcd for C₂₁H₂₃N₂O [M+H]⁺:319.1810; found: 319.1812. Anal. Calcd for C₂₁H₂₂N₂O: C, 79.21; H, 6.96; N, 8.80. Found: C, 79.30; H, 7.31; N, 8.69.</p>
 <p style="text-align: center;">4ak'</p>	<p>(E)-6a-butyl-7-butylidene-6a,7-dihydroindolo[1,2-a]quinazolin-5(6H)-one and (Z)-6a-butyl-7-butylidene-6a,7-dihydroindolo[1,2-a]quinazolin-5(6H)-one (4ak', E:Z = 24:1): The title compounds were prepared by following the general procedure 2.5 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 2k' (14 mg, 0.1 mmol) which was then purified by column chromatography using 15% EtOAc in hexane to afford yellow solid of 4ak' (12 mg, 36%). M.p.: 164–166 °C. UV-vis (CHCl₃) λ_{\max} 295 nm, ϵ_{\max} 3750. FTIR (CHCl₃, cm⁻¹) ν_{\max} 1663, 1594, 1491, 1461. ¹H NMR (500 MHz, CDCl₃) δ 8.25 (dd, <i>J</i> = 7.7, 1.9 Hz, 0.04H), 8.09 (dd, <i>J</i> = 7.8, 1.5 Hz, 0.96H), 7.68-7.62 (m, 0.08H), 7.64-7.56 (m, 1.92H), 7.48 (d, <i>J</i> = 8.0 Hz, 0.96H), 7.38 (d, <i>J</i> = 6.6 Hz, 0.04H), 7.33-7.29 (m, 0.08H) 7.22 (t, <i>J</i> = 7.7 Hz, 1H), 7.20-7.10 (m, 1.92H), 6.95-6.85 (m, 1H), 6.35 (bs, 1H), 6.17</p>



	<p>(t, $J = 8.1$ Hz, 0.04H), 5.77-5.66 (m, 0.96H), 2.76 (q, $J = 6.8$ Hz, 0.08H), 2.57 (q, $J = 7.4$ Hz, 1.92H), 2.18-2.05 (m, 1H), 1.82-1.60 (m, 4H), 1.45-1.37 (m, 0.12H), 1.28-1.22 (m, 0.12H), 1.19-1.01 (m, 5.76H), 0.96 (t, $J = 7.4$ Hz, 0.12H), 0.73 (t, $J = 7.0$ Hz, 2.88H). ^{13}C NMR (125 MHz, CDCl_3) δ 162.1, 148.3, 139.8, 138.2, 133.2, 130.4, 129.3, 128.8, 126.0, 125.1, 124.6, 123.3, 122.2, 120.5, 107.5, 80.3, 39.4, 30.4, 26.3, 22.6, 22.2, 14.0, 13.8. HRMS (+ESI) Calcd for $\text{C}_{23}\text{H}_{27}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 347.2123; found: 347.2126. Anal. Calcd for $\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}$: C, 79.73; H, 7.56; N, 8.09. Found: C, 79.79; H, 7.30; N, 7.68.</p>
 <p>4al'</p>	<p>(E)-7-ethylidene-6a-phenyl-6a,7-dihydroindolo[1,2-a]quinazolin-5(6H)-one (4al'): The title compound was prepared by following the general procedure 2.5 from indazolone 1a (21 mg, 0.1 mmol) and alkyne 21' (13 mg, 0.1 mmol) which was then purified by column chromatography using 20% EtOAc in hexane to afford white solid of 4al' (22 mg, 65%). M.p.: 209–211 °C. UV-vis (CHCl_3) λ_{max} 347 nm, ϵ_{max} 3850. FTIR (CHCl_3, cm^{-1}) ν_{max} 1666, 1591, 1491, 1463. ^1H NMR (500 MHz, CDCl_3) δ 7.99 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.51-7.44 (m, 4H), 7.28-7.17 (m, 5H), 7.14-7.10 (m, 1H), 7.02-6.98 (m, 1H), 6.61 (bs, 1H), 5.46 (q, $J = 7.3$ Hz, 1H), 2.03 (d, $J = 7.4$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 162.9, 148.7, 142.8, 142.6, 140.2, 133.2, 129.4, 128.8, 128.1, 128.0, 127.9, 126.4, 126.3, 125.6, 125.2, 123.9, 122.8, 122.2, 121.1, 107.9, 82.1, 14.4. HRMS (+ESI) Calcd for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 339.1497; found: 339.1501. Anal. Calcd for $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}$: C, 81.63; H, 5.36; N, 8.28. Found: C, 81.87; H, 5.04; N, 8.02.</p>

































































































































4ak 1H clean 1.fid
 Name of Sample: KGH-52(P)
 Spectrum No : 36176



4ak 13C clean 1.fid
 Name of Sample: KGH-52(P)
 Spectrum No : 36177

